Nasdaq gnlx.

Jan 27, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a …Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.WebStock Quote & Chart. NASDAQ: GNLX. $11.90. Nov 30, 2023 4:00 PM EST. Change. +0.2 (+1.71%). Volume. 86,169. Today's Open. $11.79. Previous Close. $11.70.NASDAQ:GNLX. Exchange/Ticker 2: N/A. Latest Market Cap: $311,897,408. BioCentury | Aug 28, 2023. Management Tracks. Kurt Graves takes top spot at i2o. Plus ...

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the ...Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have set an average share price target of $34.33. The firm's second quarter results saw it outline $27.1 million cash in hand, which, along with other ...May 15, 2023 · Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...

View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news. GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...

Genelux press release (NASDAQ:GNLX): Q2 GAAP EPS of -$0.23.; At June 30, 2023, the company had cash on hand in the amount of $27.1 million. Net loss was $5.8 million for the second quarter of 2023 ...Top 25 Mutual Funds Where Should I Retire? Top 25 ETFs MarketWatch Picks Close Search Overlay $749.20K Ex-Dividend Date % of Float Shorted Oct. 27, 2023 at 1:30 …Genelux (NASDAQ:GNLX) opened up its shares for public trading for the first time since it filed for IPO in June 2022. The company agreed to initially offer 2.50 million shares to the public at $6.00 per share. ... For its IPO, GNLX agreed to offer 2.50 million shares at a price of $6.00 per share, with an insider lock-up period of 180 days ...29. 3. 2023 ... Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation ...

WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...

Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...

Aug 14, 2023 · WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ... Genelux Corporation 10% owner discloses sale of 49,987 shares (NASDAQ:GNLX). From Seeking Alpha Oct 26, 2023. Genelux Corporation (GNLX) 10% owner, Aladar ...Genelux Corporation. WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical ...Nov 7, 2023 · The average price predicted for Genelux Corp (GNLX) by analysts is $36.00, which is $22.03 above the current market price. The public float for GNLX is 18.34M, and at present, short sellers hold a 4.76% of that float. On November 07, 2023, the average trading volume of GNLX was 223.78K shares. Top 5 AI Stocks to Buy for 2023. Genelux Corp (NASDAQ:GNLX). 11.68. Delayed Data. As of Nov 29. +1.24 / +11.85%. Today's Change. 5.35. Today|||52-Week Range. 40.98. --. Year-to-Date. QuoteWESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...GNLX. --Genelux Corporation, a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share ...

Nov 30, 2023 · 4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ... 2 days ago · Genelux IPO prices at bottom of range. Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha... 11 months ago - Market Watch. Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX...WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...

12. 6. 2023 ... ... (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common ...

Aclaris Therapeutics (NASDAQ:ACRS) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and …GNLX. --Genelux Corporation, a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share ...WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...Genelux Corporation (NASDAQ:GNLX) gained 12.9% to $30.82. Franchise Group, Inc. (NASDAQ:FRG) jumped 11.8% to $25.44. Franchise Group revealed the receipt of an unsolicited non-binding proposal to ...Genelux Corp. GNLX (U.S.: Nasdaq) Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting News Genelux Corp. No...About After Hours Quotes. Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. $202.77 1.43%. Bed Bath & Beyond Inc. Common Stock. 17. 4. 2023 ... Genelux President, CEO & Chairman Thomas Zindrick shares how being #NasdaqListed helps $GNLX reach its goals in improving the lives of the ...Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery ...

Aug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

Genelux Corp. GNLX (U.S.: Nasdaq) Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting News Genelux Corp. No...

Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...Genelux (Nasdaq:GNLX) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech GNLX Genelux NasdaqCM:GNLX …About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%. View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: …Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from ...Web26. 10. 2023 ... Genelux raised $15.9 million in January pricing shares at $6 each. The stock (NASDAQ:GNLX) closed at $18.69 on Oct. 25, a 211.5% increase. Also ...Nov 30, 2023 · 4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ... May 2014 - Present 9 years 7 months. Westlake Village, California. Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial ...Fintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ...Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions.

On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp ( NASDAQ:GNLX ). This move comes amidst a year where the insider has sold a total of 89,893 shares and …Genelux (NASDAQ:GNLX) director Szalay Aladar continued to dispose of his stake in the biopharmaceutical company. Aladar sold 42,263 shares of indirect ownership, held by The Szalay 2010 Retained ...Mar 23, 2023 · Genelux Corporation. WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical ... 52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.WebInstagram:https://instagram. forex com vs oanda spreadsbest app based bankbest investment management firmssmall company to invest WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... stock market practicecovid tests gov free GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ... stocks top movers Genelux (NASDAQ:GNLX) opened up its shares for public trading for the first time since it filed for IPO in June 2022. The company agreed to initially offer 2.50 million shares to the public at $6.00 per share. ... For its IPO, GNLX agreed to offer 2.50 million shares at a price of $6.00 per share, with an insider lock-up period of 180 days ...WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the ...Nov 24, 2023 · Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ...